Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.3
Journals
Nanomaterials
Special Issues
Smart Nanomaterials for Cancer Diagnosis and Therapy
share announcement

Smart Nanomaterials for Cancer Diagnosis and Therapy

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 4396

Special Issue Editor

Dr. Ruizhuo Ouyang

E-Mail Website
Guest Editor
School of Materials and Chemistry & Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China
Interests: cancer diagnosis and therapy; anticancer drugs; biosensors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The wide use of nanomaterials as innovative nanomedicines has guided the improved outcomes for early cancer diagnosis and therapy but still remains critically challenging due to unignorable limitations such as non-targeted distribution, weakened biocompatibility, reduced photostability, complicated fabrication, and systemic toxicity to the body. As a consequence, smart nanomaterials with controllable physicochemical and biological properties have been emerging as a promising solution to address those drawbacks of cancer detection and treatment through being effectively activated by certain specific exogenous or endogenous stimuli such as pH, temperature, pressure, enzymes, particular biological molecules, etc. Various applications of smart nanomaterials with different shapes, sizes, and compositions have thus been extensively explored in various biomedical applications including biosensors, targeted drug delivery, in vivo bioimaging, and the simultaneous diagnosis and treatment of cancer, where greatly improved selectivity and sensitivity with significantly lowered side-effects are exhibited in comparison to the currently used conventional methods. Moreover, during cancer therapy, these smart nanomaterials remain deactivated in normal cells until they reach the tumor microenvironment, which further limits their side-effects and systemic toxicities.

This Special Issue will present comprehensive research outlining the current significant achievements and latest advances in the development of diverse biomedical nanomaterials for cancer diagnosis and therapy. This includes the preparation and utilization of both inorganic and organic smart nanomaterials as efficient nanotherapeutic platforms to improve the efficiency in targeted drug delivery, in vivo bioimaging, diagnosis and treatment, and simultaneous cancer diagnosis and therapy in different responsive models. We are pleased to invite authors to contribute original research articles and review articles covering the current progress in smart nanomaterial development for nanomedicine and cancer. Potential smart nanomaterials may include, but are not limited to, the following:

  • Inorganic nanomaterials based on metal and metal oxide, quantum dots, silica, etc.;
  • Organic nanomaterials based on polymer, carbon, lipid, self-assembly, etc.;
  • Mixed nanomaterials composed of both inorganic and organic species;
  • Intelligent nanomaterials in bio-, physical and chemical properties- or multi‑responsive models.

We look forward to receiving your contributions.

Dr. Ruizhuo Ouyang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • smart nanomaterials
  • nanomedicine
  • cancer diagnosis and therapy
  • inorganic nanomaterials
  • organic nanomaterials
  • in vivo bioimaging
  • drug delivery
  • nanotheraputic platforms

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 3334 KiB  
Article
LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation
by Qingyuan Wang, Zhizheng Zhang, Dehui Qiu, Xuanxiang Mao, Zhaoxi Zhou, Tiansong Xia, Jifu Wei, Qiang Ding and Xiaobo Zhang
Nanomaterials 2022, 12(24), 4478; https://doi.org/10.3390/nano12244478 - 17 Dec 2022
Cited by 3 | Viewed by 1673
Abstract
Just-in-time evaluation of drug resistance in situ will greatly facilitate the achievement of precision cancer therapy. The rapid elevation of reactive oxygen species (ROS) is the key to chemotherapy. Hence, suppressed ROS production is an important marker for chemotherapy drug resistance. Herein, a [...] Read more.
Just-in-time evaluation of drug resistance in situ will greatly facilitate the achievement of precision cancer therapy. The rapid elevation of reactive oxygen species (ROS) is the key to chemotherapy. Hence, suppressed ROS production is an important marker for chemotherapy drug resistance. Herein, a NIR-II emission smart nanoprobe (LnNP@ZIF8, consisting of a lanthanide-doped nanoparticle (LnNP) core and metal-organic framework shell (ZIF8)) is constructed for drug delivery and in vivo NIR-II ratiometric imaging of ROS for tumor drug resistance evaluation. The drug-loaded nanoprobes release therapeutic substances for chemotherapy in the acidic tumor tissue. As the level of ROS increases, the LnNPs shows responsively descending fluorescence intensity at 1550 nm excited by 980 nm (F1550, 980Ex), while the fluorescence of the LnNPs at 1060 nm excited by 808 nm (F1060, 808Ex) is stable. Due to the ratiometric F1550, 980Ex/F1060, 808Ex value exhibiting a linear relationship with ROS concentration, NIR-II imaging results of ROS change based on this ratio can be an important basis for determining tumor drug resistance. As the chemotherapy and resistance evaluation are explored continuously in situ, the ratiometric imaging identifies drug resistance successfully within 24 h, which can greatly improve the timeliness of accurate treatment. Full article
(This article belongs to the Special Issue Smart Nanomaterials for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

18 pages, 5061 KiB  
Article
Sorafenib-Loaded Cu2−xSe Nanoparticles Boost Photothermal–Synergistic Targeted Therapy against Hepatocellular Carcinoma
by An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu and Yuhao Li
Nanomaterials 2022, 12(18), 3191; https://doi.org/10.3390/nano12183191 - 14 Sep 2022
Cited by 8 | Viewed by 1940
Abstract
Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment, has a battery of untoward side effects. Photothermal therapy (PTT) has been utilized [...] Read more.
Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment, has a battery of untoward side effects. Photothermal therapy (PTT) has been utilized as an effective adjuvant in synergy with other approaches. However, little is known about the tumoricidal efficacy of combining SOR with PTT for HCC. Herein, a novel versatile nanoparticle, Cu2−xSe@SOR@PEG (CSP), that is based on a photothermal Cu2−xSe core and SOR for simultaneously reinforcing PTT and reducing the adverse effects of SOR was constructed. The synthesized CSP exhibited a remarkably enhanced therapeutic effect upon 808 nm laser irradiation via dampening HCC cell propagation and metastasis and propelling cell apoptosis. The intravenous administration of CSP substantially suppressed tumor growth in a xenograft tumor mouse model. It was noted that the CSP manifested low toxicity and excellent biocompatibility. Together, this work indicates a promising and versatile tool that is based on synergistic PTT and molecular-targeted therapy for HCC management. Full article
(This article belongs to the Special Issue Smart Nanomaterials for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 6356 KiB  
Review
Two Hawks with One Arrow: A Review on Bifunctional Scaffolds for Photothermal Therapy and Bone Regeneration
by Yulong Zhang, Xueyu Liu, Chongrui Geng, Hongyu Shen, Qiupeng Zhang, Yuqing Miao, Jingxiang Wu, Ruizhuo Ouyang and Shuang Zhou
Nanomaterials 2023, 13(3), 551; https://doi.org/10.3390/nano13030551 - 29 Jan 2023
Cited by 15 | Viewed by 2034
Abstract
Despite the significant improvement in the survival rate of cancer patients, the total cure of bone cancer is still a knotty clinical challenge. Traditional surgical resectionof bone tumors is less than satisfactory, which inevitably results in bone defects and the inevitable residual tumor [...] Read more.
Despite the significant improvement in the survival rate of cancer patients, the total cure of bone cancer is still a knotty clinical challenge. Traditional surgical resectionof bone tumors is less than satisfactory, which inevitably results in bone defects and the inevitable residual tumor cells. For the purpose of realizing minimal invasiveness and local curative effects, photothermal therapy (PTT) under the irradiation of near-infrared light has made extensive progress in ablating tumors, and various photothermal therapeutic agents (PTAs) for the treatment of bone tumors have thus been reported in the past few years, has and have tended to focus on osteogenic bio-scaffolds modified with PTAs in order to break through the limitation that PTT lacks, osteogenic capacity. These so-called bifunctional scaffolds simultaneously ablate bone tumors and generate new tissues at the bone defects. This review summarizes the recent application progress of various bifunctional scaffolds and puts forward some practical constraints and future perspectives on bifunctional scaffolds for tumor therapy and bone regeneration: two hawks with one arrow. Full article
(This article belongs to the Special Issue Smart Nanomaterials for Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop